Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs PepsiCo, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while PepsiCo, Inc. trades at $135.83 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 23× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PEP | |
|---|---|---|
Market Cap | $8.04B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $170.44 |
52-Week Low | $241.71 | $133.81 |
Enterprise Value | $7.85B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
PepsiCo (PEP) trades at $138.49, up 0.81% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and consistent earnings growth potential, though near-term technical weakness and pricing strategy adjustments present headwinds. The stock trades at reasonable valuation multiples (P/E 17.75) with upside to analyst targets, but investors should monitor North American performance recovery and consumer pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
